Hims & Hers Under Investigation for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy HIMS?
Source: Globenewswire
- Legal Investigation Initiated: The Schall Law Firm is investigating Hims & Hers Health, Inc. for potential securities law violations, focusing on whether the company made false or misleading statements, which could undermine investor confidence and lead to stock price declines.
- FDA Statement Impact: The FDA announced plans to restrict the use of GLP-1 active pharmaceutical ingredients, with Hims & Hers accused of marketing non-FDA-approved compounded drugs, potentially facing stricter regulations that could affect its competitive position in the market.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, which could result in significant financial liabilities and loss of market share for the company.
- Stock Price Volatility: On February 9, 2026, shares of Hims & Hers fell by over 17.8%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market trust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 21.340
Low
16.50
Averages
32.95
High
60.00
Current: 21.340
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ETF Component Trading Dynamics Analysis
- Chewy Trading Surge: On Wednesday, Chewy saw over 14.6 million shares traded, with its stock price rising approximately 13.4%, indicating strong investor confidence in its growth potential, which may attract further capital inflows.
- Hims & Hers Health Decline: Hims & Hers Health's stock fell about 1.6% despite trading over 10.4 million shares, suggesting market concerns regarding its business outlook, which could impact its short-term investment appeal.
- Bentley Systems Underperformance: Within the iShares S&P Mid-Cap 400 Growth ETF, Bentley Systems traded down approximately 4.5%, indicating relative weakness in the market, which may lead investors to reassess its investment value.
- Overall ETF Trading Trends: Wednesday's ETF trading revealed unusual volumes, particularly in the IJK ETF, potentially reflecting increased market interest in mid-cap growth stocks, influencing overall market sentiment.
See More
Hims & Hers Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has initiated an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA announced plans to restrict the use of GLP-1 active pharmaceutical ingredients, with Hims & Hers accused of marketing unapproved weight loss drugs, which may lead to a decline in market trust.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, heightening the company's legal risks and potential financial losses.
- Significant Stock Drop: On February 9, 2026, shares of Hims & Hers fell by over 17.8% during afternoon trading, reflecting market concerns about the company's future prospects and a shake in investor confidence.
See More
Hims & Hers Partners with Novo Nordisk for Wegovy Launch
- Partnership Outlook: Hims & Hers has entered into an agreement with Novo Nordisk to launch the Wegovy pill, which is expected to provide new growth momentum for the company, particularly in the latter half of 2026, potentially improving its operational status significantly.
- Market Potential: The strong demand for Wegovy as a weight-loss medication could position Hims & Hers as a high-growth stock, attracting more investor interest and enhancing the overall valuation of the company.
- Strategic Significance: This partnership not only introduces a new product line for Hims & Hers but may also enhance its market position in the health and beauty sector, further driving brand recognition and expanding its customer base.
- Future Outlook: With the launch of Wegovy, Hims & Hers is poised to achieve significant sales growth by the end of 2026, further solidifying its position in the competitive health product market.
See More
Novo Nordisk and Hims & Hers Deal Sparks New Product Launches
- Product Launch Outlook: The collaboration between Hims & Hers and Novo Nordisk will introduce the Wegovy pill, expected to be the fastest GLP-1 launch in history, potentially driving significant growth for the company in 2026.
- Market Recovery Potential: Despite facing challenges in 2026, the deal with Novo Nordisk is poised to revitalize Hims & Hers' operations, enhancing the company's market performance in the coming years.
- Distribution Channel Expansion: The new agreement will broaden Hims & Hers' distribution channels, enabling more effective outreach to target customers, thereby boosting sales and market share.
- Investor Interest: With the upcoming product launch, Hims & Hers could emerge as a high-growth stock, attracting investor attention and increasing its market valuation.
See More
Hims & Hers Health, Inc. Under Investigation Following Legal Issues
- Investigation Launched: Kahn Swick & Foti, LLC has initiated an investigation into Hims & Hers Health, Inc., focusing on whether its executives breached fiduciary duties to shareholders, which could impact corporate governance.
- Partnership Termination Impact: Novo Nordisk announced the termination of its partnership with Hims in June 2025, citing the company's failure to comply with laws, potentially jeopardizing patient safety and severely damaging its market reputation.
- Securities Lawsuit Progress: Hims & Hers and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court denying the company's motion to dismiss, allowing the case to proceed and potentially resulting in significant financial liabilities.
- Investor Rights at Risk: KSF is urging long-term holders of Hims shares to provide information, indicating that the legal issues facing the company could significantly affect investor rights and increase investment risks.
See More
Novo Nordisk Shares Plummet Amidst Dismal Guidance
- Stock Price Decline: Novo Nordisk's shares have plummeted over 50% in the past year, reaching their lowest levels since early 2021, indicating investor dissatisfaction with recent performance and a pessimistic outlook for the future.
- Guidance Downgrade: The company projects a potential revenue decline of up to 13% for the current year, and despite launching a new Wegovy pill, pricing pressures have raised doubts about its growth potential, which could impact investor confidence moving forward.
- Strategic Partnership: Novo Nordisk has partnered with telehealth company Hims & Hers Health to sell its GLP-1 products on Hims' platform, a move that could drive sales growth and improve performance amid current challenges.
- Investment Opportunity: Despite facing short-term headwinds, Novo Nordisk's stock trades at just 10 times earnings, suggesting it is undervalued, and long-term investors may find an attractive entry point at this low price, especially if market sentiment improves.
See More
ETF Component Trading Dynamics Analysis
- Chewy Trading Surge: On Wednesday, Chewy saw over 14.6 million shares traded, with its stock price rising approximately 13.4%, indicating strong investor confidence in its growth potential, which may attract further capital inflows.
- Hims & Hers Health Decline: Hims & Hers Health's stock fell about 1.6% despite trading over 10.4 million shares, suggesting market concerns regarding its business outlook, which could impact its short-term investment appeal.
- Bentley Systems Underperformance: Within the iShares S&P Mid-Cap 400 Growth ETF, Bentley Systems traded down approximately 4.5%, indicating relative weakness in the market, which may lead investors to reassess its investment value.
- Overall ETF Trading Trends: Wednesday's ETF trading revealed unusual volumes, particularly in the IJK ETF, potentially reflecting increased market interest in mid-cap growth stocks, influencing overall market sentiment.
See More
Hims & Hers Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has initiated an investigation into Hims & Hers Health, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could undermine investor confidence.
- FDA Statement Impact: The FDA announced plans to restrict the use of GLP-1 active pharmaceutical ingredients, with Hims & Hers accused of marketing unapproved weight loss drugs, which may lead to a decline in market trust.
- Increased Litigation Risk: Novo Nordisk has filed a lawsuit against Hims & Hers seeking to bar the sale of compounded weight loss drugs, heightening the company's legal risks and potential financial losses.
- Significant Stock Drop: On February 9, 2026, shares of Hims & Hers fell by over 17.8% during afternoon trading, reflecting market concerns about the company's future prospects and a shake in investor confidence.
See More
Hims & Hers Partners with Novo Nordisk for Wegovy Launch
- Partnership Outlook: Hims & Hers has entered into an agreement with Novo Nordisk to launch the Wegovy pill, which is expected to provide new growth momentum for the company, particularly in the latter half of 2026, potentially improving its operational status significantly.
- Market Potential: The strong demand for Wegovy as a weight-loss medication could position Hims & Hers as a high-growth stock, attracting more investor interest and enhancing the overall valuation of the company.
- Strategic Significance: This partnership not only introduces a new product line for Hims & Hers but may also enhance its market position in the health and beauty sector, further driving brand recognition and expanding its customer base.
- Future Outlook: With the launch of Wegovy, Hims & Hers is poised to achieve significant sales growth by the end of 2026, further solidifying its position in the competitive health product market.
See More
Novo Nordisk and Hims & Hers Deal Sparks New Product Launches
- Product Launch Outlook: The collaboration between Hims & Hers and Novo Nordisk will introduce the Wegovy pill, expected to be the fastest GLP-1 launch in history, potentially driving significant growth for the company in 2026.
- Market Recovery Potential: Despite facing challenges in 2026, the deal with Novo Nordisk is poised to revitalize Hims & Hers' operations, enhancing the company's market performance in the coming years.
- Distribution Channel Expansion: The new agreement will broaden Hims & Hers' distribution channels, enabling more effective outreach to target customers, thereby boosting sales and market share.
- Investor Interest: With the upcoming product launch, Hims & Hers could emerge as a high-growth stock, attracting investor attention and increasing its market valuation.
See More
Hims & Hers Health, Inc. Under Investigation Following Legal Issues
- Investigation Launched: Kahn Swick & Foti, LLC has initiated an investigation into Hims & Hers Health, Inc., focusing on whether its executives breached fiduciary duties to shareholders, which could impact corporate governance.
- Partnership Termination Impact: Novo Nordisk announced the termination of its partnership with Hims in June 2025, citing the company's failure to comply with laws, potentially jeopardizing patient safety and severely damaging its market reputation.
- Securities Lawsuit Progress: Hims & Hers and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court denying the company's motion to dismiss, allowing the case to proceed and potentially resulting in significant financial liabilities.
- Investor Rights at Risk: KSF is urging long-term holders of Hims shares to provide information, indicating that the legal issues facing the company could significantly affect investor rights and increase investment risks.
See More
Novo Nordisk Shares Plummet Amidst Dismal Guidance
- Stock Price Decline: Novo Nordisk's shares have plummeted over 50% in the past year, reaching their lowest levels since early 2021, indicating investor dissatisfaction with recent performance and a pessimistic outlook for the future.
- Guidance Downgrade: The company projects a potential revenue decline of up to 13% for the current year, and despite launching a new Wegovy pill, pricing pressures have raised doubts about its growth potential, which could impact investor confidence moving forward.
- Strategic Partnership: Novo Nordisk has partnered with telehealth company Hims & Hers Health to sell its GLP-1 products on Hims' platform, a move that could drive sales growth and improve performance amid current challenges.
- Investment Opportunity: Despite facing short-term headwinds, Novo Nordisk's stock trades at just 10 times earnings, suggesting it is undervalued, and long-term investors may find an attractive entry point at this low price, especially if market sentiment improves.
See More
